|
Index | - | P/E | - | EPS (ttm) | -1.67 | Insider Own | 0.70% | Shs Outstand | 12.66M | Perf Week | 13.21% |
Market Cap | 6.00M | Forward P/E | - | EPS next Y | -0.67 | Insider Trans | 0.00% | Shs Float | 12.40M | Perf Month | 16.01% |
Income | -16.40M | PEG | - | EPS next Q | -0.24 | Inst Own | 23.40% | Short Float | 1.47% | Perf Quarter | -28.02% |
Sales | - | P/S | - | EPS this Y | -0.30% | Inst Trans | 0.81% | Short Ratio | 0.62 | Perf Half Y | -70.20% |
Book/sh | 0.73 | P/B | 0.62 | EPS next Y | 1.20% | ROA | -79.70% | Target Price | 7.12 | Perf Year | -87.60% |
Cash/sh | 0.59 | P/C | 0.76 | EPS next 5Y | - | ROE | -131.90% | 52W Range | 0.35 - 6.43 | Perf YTD | -70.20% |
Dividend | - | P/FCF | - | EPS past 5Y | 39.90% | ROI | - | 52W High | -93.00% | Beta | 0.81 |
Dividend % | - | Quick Ratio | 5.60 | Sales past 5Y | - | Gross Margin | - | 52W Low | 29.80% | ATR | 0.06 |
Employees | 14 | Current Ratio | 5.60 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 56.74 | Volatility | 15.27% 17.14% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | -28.70% | Profit Margin | - | Rel Volume | 0.19 | Prev Close | 0.45 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 294.23K | Price | 0.45 |
Recom | 2.00 | SMA20 | 11.52% | SMA50 | 5.09% | SMA200 | -54.04% | Volume | 56,416 | Change | 0.00% |
![]() |
|
![]() | ||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. | ||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite